| 1 |
Wiśniewska A, Czepiel K, Stachowicz A, Pomierny B, Kuś K, Kiepura A, Stachyra K, Surmiak M, Madej J, Olszanecki R, Suski M. The antiatherosclerotic action of 1G244 - An inhibitor of dipeptidyl peptidases 8/9 - is mediated by the induction of macrophage death. Eur J Pharmacol 2023;:175566. [PMID: 36739078 DOI: 10.1016/j.ejphar.2023.175566] [Reference Citation Analysis]
|
| 2 |
Yin Y, Tan M, Han L, Zhang L, Zhang Y, Zhang J, Pan W, Bai J, Jiang T, Li H. The Hippo kinases MST1/2 in cardiovascular and metabolic diseases: A promising therapeutic target option for pharmacotherapy. Acta Pharmaceutica Sinica B 2023. [DOI: 10.1016/j.apsb.2023.01.015] [Reference Citation Analysis]
|
| 3 |
Eligini S, Gianazza E, Mallia A, Ghilardi S, Banfi C. Macrophage Phenotyping in Atherosclerosis by Proteomics. IJMS 2023;24:2613. [DOI: 10.3390/ijms24032613] [Reference Citation Analysis]
|
| 4 |
Han J, Song Y, Yao W, Zhou J, Du Y, Xu T. Follicle-Stimulating Hormone Provokes Macrophages to Secrete IL-1β Contributing to Atherosclerosis Progression. The Journal of Immunology 2023;210:25-32. [DOI: 10.4049/jimmunol.2200475] [Reference Citation Analysis]
|
| 5 |
Gitler A, Vanacker L, De Couck M, De Leeuw I, Gidron Y. Neuromodulation Applied to Diseases: The Case of HRV Biofeedback. JCM 2022;11:5927. [DOI: 10.3390/jcm11195927] [Reference Citation Analysis]
|
| 6 |
Li B, Wang C, Lu P, Ji Y, Wang X, Liu C, Lu X, Xu X, Wang X. IDH1 Promotes Foam Cell Formation by Aggravating Macrophage Ferroptosis. Biology 2022;11:1392. [DOI: 10.3390/biology11101392] [Reference Citation Analysis]
|
| 7 |
Ma M, Liu Y, Wang L, Yang R, Li Z, Gao S, Li L, Yu C. Relationship Between Monocyte-to-Lymphocyte Ratio as Well as Other Leukocyte-Derived Ratios and Carotid Plaques in Patients with Coronary Heart Disease: A RCSCD-TCM Study. J Inflamm Res 2022;15:5141-56. [PMID: 36105384 DOI: 10.2147/JIR.S375759] [Reference Citation Analysis]
|
| 8 |
Jin Z, Chen T, Zhu Z, Xu B, Yan D. The role of TRIM59 in immunity and immune-related diseases. Int Rev Immunol 2022;:1-8. [PMID: 35975813 DOI: 10.1080/08830185.2022.2102618] [Reference Citation Analysis]
|
| 9 |
Wang G, Jing S, Liu G, Guo X, Zhao W, Jia X, Zheng M, Tan W, Singh A. miR-99a-5p: A Potential New Therapy for Atherosclerosis by Targeting mTOR and Then Inhibiting NLRP3 Inflammasome Activation and Promoting Macrophage Autophagy. Disease Markers 2022;2022:1-13. [DOI: 10.1155/2022/7172583] [Reference Citation Analysis]
|
| 10 |
Zou J, Xu C, Zhao ZW, Yin SH, Wang G. Asprosin inhibits macrophage lipid accumulation and reduces atherosclerotic burden by up-regulating ABCA1 and ABCG1 expression via the p38/Elk-1 pathway. J Transl Med 2022;20:337. [PMID: 35902881 DOI: 10.1186/s12967-022-03542-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 11 |
Song L, Zhang J, Ma D, Fan Y, Lai R, Tian W, Zhang Z, Ju J, Xu H. A Bibliometric and Knowledge-Map Analysis of Macrophage Polarization in Atherosclerosis From 2001 to 2021. Front Immunol 2022;13:910444. [DOI: 10.3389/fimmu.2022.910444] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 12 |
Zheng Y, Li Y, Ran X, Wang D, Zheng X, Zhang M, Yu B, Sun Y, Wu J. Mettl14 mediates the inflammatory response of macrophages in atherosclerosis through the NF-κB/IL-6 signaling pathway. Cell Mol Life Sci 2022;79. [DOI: 10.1007/s00018-022-04331-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 13 |
Yu Z, Bu G. Attenuating oxidized low density lipoprotein (ox-LDL)-induced macrophages damage via inhibiting C-type lectin domain family 2 (CLEC2) expression through janus kinase 1 (JAK1)/ signal transducers and activators of transcription-1 (STAT1) pathway. Bioengineered 2022;13:6440-9. [PMID: 35486473 DOI: 10.1080/21655979.2022.2044253] [Reference Citation Analysis]
|
| 14 |
Germena G, Zelarayán LC, Hinkel R. Cellular Chitchatting: Exploring the Role of Exosomes as Cardiovascular Risk Factors. Front Cell Dev Biol 2022;10:860005. [DOI: 10.3389/fcell.2022.860005] [Reference Citation Analysis]
|
| 15 |
Aprotosoaie AC, Costache A, Costache I. Therapeutic Strategies and Chemoprevention of Atherosclerosis: What Do We Know and Where Do We Go? Pharmaceutics 2022;14:722. [DOI: 10.3390/pharmaceutics14040722] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 16 |
Song Y, Li S, He C. PPARγ Gene Polymorphisms, Metabolic Disorders, and Coronary Artery Disease. Front Cardiovasc Med 2022;9:808929. [DOI: 10.3389/fcvm.2022.808929] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 17 |
Vekic J, Zeljkovic A, Cicero AFG, Janez A, Stoian AP, Sonmez A, Rizzo M. Atherosclerosis Development and Progression: The Role of Atherogenic Small, Dense LDL. Medicina 2022;58:299. [DOI: 10.3390/medicina58020299] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
|
